Project Grant R01HL183658
Award Date 8/15/26
Completion Date 7/31/31
Dollars Obligated $705K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $768,414 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic profiling research examining the relationship between idiopathic pulmonary fibrosis and cardiovascular disease. The research identifies shared molecular mechanisms linking pulmonary fibrosis and cardiovascular disease through blood-based and tissue analysis. The project defines shared...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Cornell University $734,475 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanobiological regulation of ventricular maturation. The research will test the hypothesis that local mechanical stress operates a Piezo-Notch-YAP mechanobiological switch governing temporal compact and trabecular ventricular wall growth versus structural maturation dynamics. The...
- The National Heart Lung and Blood Institute awarded Weill Medical College of Cornell University $936,356 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, for the PE-TRACT Extend Study, a prospective cohort investigation of chronic thromboembolic disease following intermediate-risk pulmonary embolism treatment. The study extends the NHLBI-funded PE-TRACT randomized trial of catheter-directed therapy for acute PE by following the parent study population beyond the...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Texas at Austin $428,327 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop patient-specific, pre-procedural planning simulation tools for tricuspid valve repair. The project addresses tricuspid valve regurgitation, a condition affecting more than 1.6 million Americans, which is repaired in fewer than 10,000 patients annually due to low success...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $1,657,587 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect molecular pathways controlling human pacemaker development. The recipient will conduct research aimed at identifying key transcriptional regulators of sinoatrial node (SAN) differentiation using CRISPR interference and activation in human pluripotent stem cells, then validate findings in...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $100,805 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop translational extended reality (XR) and artificial intelligence technologies integrated with dynamic soft robotic hearts for immersive clinical training and intraoperative guidance in interventional cardiology. The project addresses critical limitations in structural heart intervention procedures...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $218,728 on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop computational and experimental methods for studying noncoding RNAs in hematopoiesis. The recipient will develop a computational pipeline to process and analyze single-cell total RNA sequencing (scTRS) data, a method that captures modified and non-polyadenylated noncoding RNAs—including long...